PNC Financial Services Group Inc. Has $292,000 Holdings in LivaNova PLC (NASDAQ:LIVN)

PNC Financial Services Group Inc. boosted its stake in LivaNova PLC (NASDAQ:LIVN) by 29.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,311 shares of the company’s stock after purchasing an additional 1,424 shares during the quarter. PNC Financial Services Group Inc.’s holdings in LivaNova were worth $292,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of LIVN. Point72 Asset Management L.P. raised its stake in LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after purchasing an additional 806,374 shares in the last quarter. Raymond James Financial Inc. acquired a new position in LivaNova in the fourth quarter valued at about $9,645,000. Point72 DIFC Ltd raised its stake in LivaNova by 75,799.6% in the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock valued at $9,531,000 after purchasing an additional 181,161 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in LivaNova by 286.4% in the third quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock valued at $10,889,000 after purchasing an additional 153,611 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in LivaNova by 17.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock valued at $32,678,000 after purchasing an additional 93,311 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on LIVN. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Barclays decreased their target price on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. Mizuho decreased their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $61.17.

LivaNova Stock Performance

NASDAQ:LIVN opened at $39.48 on Friday. The stock has a market cap of $2.15 billion, a P/E ratio of 94.00 and a beta of 1.10. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock’s 50-day moving average is $45.31 and its 200-day moving average is $48.75. LivaNova PLC has a 1-year low of $36.85 and a 1-year high of $64.48.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.